Hansa Biopharma, a leading manufacturer of immunomodulatory enzyme technology for rare IgG-mediated diseases, has announced the appointment of Achim Kaufhold as Chief Medical Officer. Kaufhold will report to Hansa CEO Søren Tulstrup.
"I am very happy that we have managed to attract Achim Kaufhold as CMO," said Tulstrup. "2020 promises to be a transformative year for our company with the potential EU regulatory approval of imlifidase in kidney transplantation and top-line data from the first phase 2 trial in autoimmune diseases. Achim Kaufhold's extensive international experience within the pharmaceutical industry, as well as his track record from successfully bringing products all the way from the laboratory to the bedside of the patient, will add substantial value to our team".
Kaufhold brings significant pharmaceutical industry experience to the team at Hansa as well as first-hand knowledge of taking drugs from early discovery to market development. Kaufhold has more than 25 years of experience in vaccine development, most recently working as Chief Medical officer and Member of the Executive Committee at Basilea Pharmaceutica.
"I am excited to join Hansa Biopharm, and I am really impressed by the science and the potential that the immunomodulatory enzyme technology offers across a broad range of indications", said Kaufhold. "I look forward to contributing to the further development of a commercial stage company and help leveraging the unique technology platform also beyond kidney transplantation."